Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Next Previous
Trial Profile

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganciclovir (Primary) ; Nanatinostat/valganciclovir combination therapy (Primary) ; Valganciclovir (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms NAVAL-1
  • Sponsors Viracta Therapeutics

Most Recent Events

  • 26 Dec 2024 According to a Viracta media release, the company has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial).
  • 26 Dec 2024 Status changed from recruiting to discontinued, According to a Viracta media release.
  • 14 Aug 2024 According to a Viracta media release, R &D expenses were appro. $6.5 and $16.5 MM for the 3 and 6 months ended Jun 30, 2024, respectively, compared to appro. $8.2 and $15.8 MM for the same periods in 2023. The decrease in R & D expenses for the 3 months ended Jun 30, 2024 compared to the same period in 2023, was driven by decreases in costs incurred to support the advancement and expansion of our clinical development programs, including incremental costs to support this trials costs.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top